Date: 2016-01-12
Type of information: Establishment of a new subsidiary in the US
Compound: eXtellia Therapeutics
Company: Intellia Therapeutics (USA - MA)
Therapeutic area: Autoimmune diseases – Inflammatory diseases - Cancer - Oncology
Type agreement: establishment of a new subsidiary in the US
Action mechanism: CRISPR/Cas gene-editing technology/gene therapy. CRISPR/Cas9 is a gene-editing technology that can cut DNA in precise locations, providing the opportunity to selectively knock out, repair or insert specific genetic sequences. It has potential application across multiple therapeutic areas including autoimmune diseases, metabolic and blood disorders, cancer and rare and genetic-based diseases. For ex vivo applications, cells are removed from the patient and edited in culture and then returned to the patient. The in vivo approach packages CRISPR/Cas9 in a delivery vehicle which is administered directly into the patient.
Disease:
Details: * On January 12, 2016, Intellia Therapeutics has launched a new division, eXtellia Therapeutics, with the intent of focusing resources and research on ex vivo applications of the novel technology, CRISPR/Cas9. As in vivo and ex vivo programs require different competencies in research, manufacturing and commercialization, eXtellia Therapeutics is being launched to accelerate Intellia’s efforts in areas of significant unmet medical need – immuno-oncology, autoimmune and inflammatory diseases – using an ex vivo approach. Intellia will continue its in vivo programs and strategy through a dedicated scientific team. eXtellia complements Intellia’s five-year collaboration with Novartis, announced in January, 2015, which is focused on CRISPR/Cas9 applications with chimeric antigen receptor T-cells (CART)- and Hematopoietic Stem Cell (HSC)-based therapies. Intellia scientists will continue to work closely with Novartis. eXtellia scientists intend to leverage the potential of CRISPR/Cas9 across a variety of immune cells, such as natural killer cells and T-cells, to develop therapies for patients where treatment needs are inadequately addressed.
Financial terms:
Latest news:
